|Articles|February 11, 2016

Canadian Drug Developer To Use OmniComm’s EDC

OmniComm’s TrialMaster EDC suite will be used for the collection of clinical data during a five year term in global Phase I to Phase III clinical studies.

OmniComm Systems, a leading provider of clinical data management technology, announced the signing of a five-year agreement with a Canadian pharmaceutical drug developer. OmniComm’s TrialMaster electronic data capture (EDC) suite will be used for the collection of clinical data during this five year term in numerous global trials spanning Phase I to Phase III clinical studies.

Read the full release.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Canadian Drug Developer To Use OmniComm’s EDC

Related Content

FDA Pauses Real-Time Release of Drug Rejection Letters While Working to Formalize Policy

Why Rebuilding Patient Pipelines from Scratch for Every Study Has to Stop

Bringing the Voice of Clinical Practice and Patients into Drug Development

ACT Brief: Single Pivotal Trial Stakes, Configurable FSP Strategy, and G-CSF Biosimilar Portfolio Expansion

Tailoring Your FSP Approach: Why One Model Doesn’t Fit Every Trial

Trending on Applied Clinical Trials Online

FDA Pauses Real-Time Release of Drug Rejection Letters While Working to Formalize Policy

ACT Brief: Simplifying Trials Through Selective Safety Data, AI-Driven Site Partnerships, and Biopharma Strategic Pivots

ACT Brief: Single Pivotal Trial Stakes, Configurable FSP Strategy, and G-CSF Biosimilar Portfolio Expansion

ACT Brief: Multimodal AI Systems Architecture, Trust-Based Trial Recruitment, and Big Pharma AI Transformation

AI-Enabled Sites and the Future of Trial Planning: Q&A with Liz Beatty, Inato